Acumen to present topline results from Phase 1 study of ACU193

Acumen Pharmaceuticals will present topline results from a Phase 1 trial of its candidate ACU193, the first clinical stage AbetaO-directed antibody therapy, at the Alzheimer’s Association International Conference 2023 taking place in Amsterdam, Netherlands and online from July 16-20, 2023. As part of a Featured Research Session – Developing Topics platform, four presentations will be made that discuss the Phase 1 trial. Decades of research have shown that soluble AbetaOs are a distinctly toxic form of Abeta, based on their propensity to bind to neurons, disrupt synapses and contribute to tau hyper-phosphorylation. ACU193 is a humanized monoclonal antibody that selectively targets toxic soluble AbetaOs and may prevent AbetaOs from binding to synapses and disrupting neuronal function. Topline INTERCEPT-AD data will be presented in a Featured Research Session as part of the Developing Topics program on Sunday, July 16, 2023 from 8 a.m. – 8:45 a.m. CEST. The session will be co-chaired by Dr. Eric Siemers, Acumen’s Chief Medical Officer, and Dr. Kimball Johnson, Medical Director of iResearch Atlanta and iResearch Savannah and an INTERCEPT-AD trial investigator.